Abstract:Prevention of hemorrhage secondary to thrombocytopenia has generally been managed by the transfusion of platelets. The need for such transfusion is related to the depth and duration of "critical" thrombocytopenia, a level that until recently was hotly debated. However a number of clinical trials have established that transfusion at a platelet count greater than 10 x 10(9)/L was safe in the absence of factors associated with increased tendency to bleed. Trying to predict which patients are at risk of bleeding due to thrombocytopenia has proven difficult outside of those scenarios that inevitably cause severe thrombocytopenia, such as treatment of leukemia and myeloablative chemotherapy with stem cell support. Models have been proposed but have yet to be validated. Of greater importance is the need for proof that intensive treatment of solid tumours with growth tactor support leads to improved outcomes. The discovery of platelet growth factors raised expectations that an effective method for abrogating thrombocytopenia would be soon available in the clinic. The cytokines initially described were pleiotropic in nature, and stimulation of platelet production was generally modest. However, one of these agents, interleukin-11, was successfully shown to reduce the incidence of severe thrombocytopenia in patients receiving dose-intensive chemotherapy, and has now received approval from the FDA for this purpose. Initial clinical trials of thrombopoietin (TPO), the central regulator of megakaryocytopoiesis and thrombopoiesis, and its analogues showed these agents to be the most potent stimulators of thrombopoiesis and to be associated with few adverse effects. They have also been shown to enhance platelet recovery after chemotherapy, but early results from trials investigating their ability to prevent severe thrombocytopenia associated with the treatment of leukemia and bone marrow transplantation have been disappointing. In addition, subcutaneous administration of one of these agents, megakaryocyte growth and development factor, has been shown to induce the formation of antibodies that neutralize native TPO and cause thrombocytopenia. TPO remains a promising therapeutic agent, however its potential application is more limited than initially anticipated, and there are a number of obstacles to overcome before it finds an importance use in the clinic.

The Role of Bone Marrow Microenvironment in Platelet Production and Their Implications for the Treatment of Thrombocytopenic Diseases

Abnormalities Of The Bone Marrow Immune Microenvironment In Patients With Prolonged Isolated Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation

The Regulation of Platelet Production and Therapeutic Drugs

Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia

Epigenetic regulation of megakaryopoiesis and platelet formation

<i>In</i> <i>vitro</i> Generation of Megakaryocytes and Platelets

A modern overview of the process of platelet formation (thrombocytopoiesis) and its dependence on several factors

Developments in the Production of Platelets from Stem Cells (Review)

The structure, biology and potential therapeutic applications of recombinant thrombopoietin

Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective

The impact of thrombopoietin on clinical practice

General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors

The Role of Bone Marrow Stromal Cells in Blood Diseases and Clinical Significance As a Crucial Part of the Hematopoietic Microenvironment

Platelet biology and functions: new concepts and clinical perspectives

A circle of life: platelet and megakaryocyte cytoskeleton dynamics in health and disease

Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production

Why Thromboembolism Occurs in Some Patients with Thrombocytopenia and Treatment Strategies

Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives

The bone marrow is the primary site of thrombopoiesis

ROLE OF OSTEOBLASTS IN THE HEMATOPOIETIC MICROENVIRONMENT OF BONE MARROW AND REGULATORY PATHWAYS AND MECHANISMS

Platelets and the Tumor Cell Microenvironment